ArticleJACC. Advances2026
Quantitative Proteomics of Plasma-Derived Extracellular Vesicles Reveals a Plasminogen-Centered Protein Network in Transthyretin Cardiac Amyloidosis.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of patients with transthyretin cardiac amyloidosis (ATTR) remains poor; this is primarily due to late diagnosis, when irreversible damage has already occurred. Circulating levels of transthyretin or other plasma markers have little value for diagnosis. Although extracellular vesicles (EVs) (key mediators of intercellular communication) may reflect disease-specific molecular changes, their protein cargo has not yet been explored in the context of ATTR cardiomyopathy (ATTR-CM).
objectivesWe evaluated whether cardiac amyloidosis alters the proteome of circulating EVs and assessed whether these changes define signature of ATTR.
methodsPlasma EVs were prospectively isolated by ultracentrifugation from 41 patients with confirmed ATTR-CM (ATTR+ group; wild-type ATTR and variant ATTR) and 24 frequency-matched patients with nonamyloid cardiomyopathy (ATTR- group), all referred to the Referral Center for Cardiac Amyloidosis (Henri Mondor Hospital, Créteil, France). EVs were characterized by flow cytometry and analyzed by quantitative liquid chromatography mass spectrometry/mass spectrometry proteomics.
resultsATTR+ patients had a distinct signature enriched in proteins associated with vascular homeostasis, coagulation, and inflammation. At least 18 of these proteins formed an interconnected network centered on plasmin/plasminogen. Notably, EV levels of transthyretin and plasminogen were elevated, whereas the level of alpha2-antiplasmin (plasmin's primary inhibitor) was low. This imbalance is particularly relevant because plasmin is known to promote amyloidogenesis via transthyretin cleavage.
conclusionsThese exploratory findings highlight a plasmin/plasminogen-centered protein network linking fibrinolysis, complement activation, and vascular inflammation to ATTR pathophysiology, and suggest that plasma EV proteomics warrant further evaluation as a minimally invasive approach for disease monitoring and biomarker discovery in ATTR-CM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.